Custom cancer vaccine trial aims to train immune system to fight melanoma
NCT ID NCT04930783
Summary
This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor, can be safely combined with other immune-boosting drugs to treat melanoma. The goal is to see if this combination helps the body's immune system better recognize and attack cancer cells. About 30 people with certain stages of melanoma will receive the treatment for up to two years and be followed for five years to monitor safety and immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.